The envelope proteins of varicella-zoster virus (VZV) are highly immunogenic and one of the most abundant is glycoprotein E (gE). However, its immunodominant regions and epitopes have not been identified. In this study, using human sera from individuals with recent varicella or zoster infections, we have localized antigenic sequences of gE using recombinant hybrid Ty-virus-like particles (VLPs) carrying overlapping fragments of the gE protein. gE(1-134)-VLPs (particles carrying amino acids 1-134 of gE) and, to a lesser extent, gE(101-161)-VLPs were found to be the most antigenic when tested by Western blotting and ELISA. Other fragments of gE (spanning residues 161-623) showed weak or no antigenicity. Pepscan analysis of human sera on overlapping synthetic peptides representing residues 1-135 of gE revealed that the most antigenic region was between residues 50 and 135. Three immunodominant sequences (residues 86-105, 116-135, and, to a lesser extent, 56-75) were detected using sera from both varicella and zoster patients. All sera from varicella, but not zoster, patients reacted strongly with an epitope in peptide 66-85. Other epitopes were recognized weakly by some varicella or zoster sera. More sera need to be tested to assess the potential disease specificity of these epitopes. The neutralizing monoclonal antibody (MAb) IF-B9 reacted with residues 71-90; however, another neutralizing MAb, SG1A, which bound to both gE(1-134)-VLPs and gE(101-161)-VLPs did not bind to any peptide. The identification of immunodominant sequences of gE will help toward the development of a subunit VZV vaccine. ᭧
INTRODUCTION
led to the recommendation that there should be a routine vaccination program for healthy children (Lieu et al., Varicella-zoster virus (VZV) is the etiologic agent of 1994). chickenpox (varicella) and shingles (zoster), and is a Active immunization currently involves the use of live member of the family Herpesviridae. VZV is highly infecvaccine strains and the Oka live varicella vaccine (Takatious and is spread by airborne droplets. The initial site hashi et al., 1974) is produced commercially by several of infection may be the conjunctiva, the upper respiratory companies. In various large, well-controlled trials, the tract, or both. VZV becomes latent in dorsal root and live VZV vaccine has proved to be effective in inducing cranial nerve ganglia with reactivation and recrudeshigh and durable VZV-specific antibody and cell-medicence as shingles in later life. This reactivation may be ated responses and protection against disease (Asano caused by immunosuppression or other ill-defined mechet al., 1985; Baba et al., 1977; Gershon et al., 1986 Gershon et al., , 1988 . anisms and is associated with depressed cell-mediated There are, however, several problems with the live vacimmunity (Grose, 1982) . In industrialized countries, chickcine which have restricted its use; for example, there is enpox is predominantly a childhood disease but it is good evidence that the vaccine virus may later reactivate often a more severe disease if it occurs in adults and to cause zoster (particularly in immunosuppressed chilimmunocompromised children (Gershon, 1975) . It has dren); there are doubts with regard to the long-term effibeen estimated that, worldwide, there may be 57 million cacy of the vaccine; and it is ineffective in children under cases of chickenpox in children per year and an effective 6 months of age due to the presence of maternal antibodmass childhood vaccination program could reduce the ies . It is evident that a low cost, safe, and number of cases of chickenpox per year by 78% (Preblud potent subunit VZV vaccine would be highly advantaet al., 1985) . A more recent cost-benefit analysis has geous over the present live vaccine and could be introduced into mass vaccination programs for normal children.
nm in diameter. The icosahedral nucleocapsid measures We devised a strategy, therefore, to identify the immunodominant regions of gE using a recombinant particu-100 nm in diameter and is surrounded by a lipid envelope which contains the viral glycoproteins. The VZV envelope late antigen production and presentation system, hybrid Ty-VLPs, and Pepscan analysis. The particulate presenglycoproteins have been classified as gE, gB, gH, gI, gC, and gL depending upon their abundance and immunogetation system is based on the self-assembling properties of a protein, p1, encoded by the TYA gene of the yeast nicity (Grose, 1990) . The publication of the complete virus sequence (Davison and Scott, 1986 ) has aided progress retrotransposon, Ty. When TYA is massively overexpressed, very high yields of virus-like particles (VLPs) can toward elucidating the important protective antigens of varicella in order to develop a subunit vaccine. The major be obtained (Adams et al., 1987a,b) . By overexpressing hybrid TYA:antigen genes in yeast, we have shown that immunoreactive proteins in Western blot analysis of sera from patients with varicella and zoster are found in the the resulting p1 fusion proteins still assemble into particles. The result is a high yield of particulate, polyvalent 78-to 114-kDa region, with other reactive proteins found at 32, 36, 66, and 220 kDa. These reactive bands include antigen. These hybrid VLPs are potent immunogens, eliciting humoral and cell-mediated immunity when injected the envelope glycoproteins and the nucleocapsid complex known as p32/p36 or assembly protein (Dubey et into experimental animals (Griffiths et al., 1991; Harris et al., 1992; Mills et al., 1991) and humans (Martin et al., al., 1988; Harper et al., 1988; Harper and Grose, 1989) . Antibodies to the glycoproteins, particularly gE, gB, and 1993). Because of their particulate nature, hybrid VLPs can be purified using straightforward biophysical methgH, predominate after natural infection and vaccination (Harper et al., 1990) and they can effectively neutralize ods resulting in substantial yields and high levels of purity (Burns et al., 1991) . the virus (Arvin et al., 1986; Forghani et al., 1990; Keller et al., 1984) . Maternal antibodies are protective in young
The approach we have taken to identify immunodominant regions of gE was to insert overlapping fragments babies, further highlighting the role of antibody in protection.
of the gE gene into our standard VLP yeast expression system. The p1-gE fragment fusion proteins were then It is now well established that cell-mediated immunity is a vital component for protection against primary variexpressed in yeast and particle formation and antigenicity assessed. The antigenicity was evaluated using sera cella infection and against zoster and a cellular response can be detected against the glycoproteins and against from individuals with recent chickenpox and zoster infections and also neutralizing mouse MAbs. Having defined the immediate early protein IE62 in infected or vaccinated individuals (reviewed in Arvin, 1992) . In particular, gE, gH, the immunodominant fragment of gE using VLPs, the position of linear B cell epitopes within that fragment and IE62 have been shown to stimulate cell-mediated immunity in humans and in guinea pigs (Giller et al., was then established by Pepscan analysis. Sera were tested for reactivity against peptides of 20 amino acids 1989; Arvin, 1994) . Furthermore, immunization with IE62 protein protected guinea pigs against challenge (Sabella in length, overlapping by 15, representing the most antigenic fragment (residues 1-134) of gE. et al., 1993) . One or more of these proteins may be required for an effective subunit vaccine. gE is the most abundant and immunogenic of the virion MATERIALS AND METHODS envelope glycoproteins (Keller et al., 1984; Weigle and Cloning of gE DNA fragments from genomic VZV DNA Grose, 1983) . It is encoded by VZV gene 68 and the by PCR primary translation product of 73 kDa is processed to the mature glycosylated form of 98 kDa. There is direct Fragments spanning the gE open reading frame were generated from genomic DNA derived from VZV isolate evidence that gE induces both neutralizing antibodies and T-helper cell responses (Arvin et al., 1986 (Arvin et al., , 1987 H-551 (Harper et al., 1988) . PCR was carried out in a total volume of 50 ml with 200 ng template DNA, 16 pmol Forghani et al., 1990; Hayward et al., 1989) and contains epitopes recognized by CD4
/ and CD8 / cytotoxic lymof each primer, 1 mM each dNTP (Pharmacia) in PCR buffer (10 mM KCl, 10 mM (NH 4 ) 2 SO 4 , 20 mM Tris-HCl phocytes from VZV-infected individuals (Hayward et al., 1989; Arvin, 1992 Arvin, , 1994 . Virus neutralization has been [pH 8.8], 2 mM MgSO 4 ) with 2 units Vent R DNA polymerase (New England Biolabs). Samples were amplified by studied using panels of monoclonal antibodies (MAbs) against gE and at least three distinct immunogenic doan initial round of 95Њ denaturation (2 min), 55Њ annealing (1 min), and 70Њ extension (5 min) followed by 30 rounds mains have been identified (Forghani et al., 1990) . The first contains two complement-dependent neutralizing of 95Њ for 1 min, 55Њ for 1 min, and 70Њ for 3 min with a final 30-min step at 25Њ. The PCR oligonucleotide primers epitopes. The second contains five complement-dependent, overlapping epitopes and one nonneutralizing epiwere designed to incorporate an 8 base pair ''stuffer fragment'' and either BglII or BamHI restriction endonutope. The third contains a complement-dependent (but complement-enhanced) epitope. The location of these clease sites. The PCR products were visualized with ethidium bromide after electrophoresis through a 1% epitopes has not been mapped. agarose gel and the bands were sized against uX174/ followed by size-exclusion chromatography as previously described (Burns et al., 1991) . This material is generally HaeIII DNA (Promega Ltd.). The gE PCR fragments were treated with proteinase K, digested with BglII and BamHI, between 80 and 95% pure. and purified on a 1% agarose gel. The amplified DNA was transferred by electroelution on to DEAE membrane Viral antigen, human sera, and MAbs (Schleicher and Schuell Ltd.; 0.45 mm; NA45) and recovered by elution into high-salt buffer.
VZV antigen was prepared from the H-551 VZV isolate. The virus was cultured in MRC5 cells and then Construction of plasmids extracted using glycine/NaCl buffer (pH 9.6). Pooled sera from 6 individuals with recent zoster infection Recombinant plasmids were constructed by standard (PZ6) and 17 individual sera from people with recent cloning procedures (Sambrook et al., 1989) . The PCR chickenpox or zoster infections were collected at St. fragments encoding gE fragments were inserted as BglII Bartholomews Hospital and stored in aliquots at 020Њ. or BglII/BamHI cassettes into the multiple cloning site
The murine MAb IF-B9 is specific for gE and was obof the modified transfer vector pSP64 (Promega). Fragtained from Dr. J. Taylor-Weideman (University of Camment 2 of gE contains an internal BglII site and was bridge). The neutralizing murine MAb SG1A was purtherefore cloned as two separate fragments (see Table  chased from VIRO Research Inc. 1). Recombinant plasmids were identified by restriction analysis and purified using QIAGEN columns (Hybaid). The gE DNA fragments were then excised from the trans-SDS-PAGE and Western blot analysis fer vector by digestion with BglII or BglII/BamHI, purified from an agarose gel as previously described and ligated Denaturing SDS-PAGE was performed according to to the truncated TYA gene of vector pOGS40. The expres- Laemmli (1970) using the Mini-protean II (Bio-Rad) appasion of this vector in yeast is under the control of a PGKratus. Gels contained 12.5% acrylamide/bisacrylamide, GAL hybrid inducible promoter (Adams et al., 1991) . The ratio 37:1 (Sigma, A-6050). The samples were diluted (1:1) nucleotide sequence of the constructions were conin loading buffer and boiled for 3-5 min. The denatured firmed by sequencing using Sequenase (United States samples were applied on to the gel at concentrations of Biochemical). 0.5-5 mg/lane. The electrophoresis was performed at 200 V. The gel was stained with Coomassie blue and Production of hybrid gE-VLPs in yeast then destained in methanol (20% v/v) and glacial acetic acid (10% v/v). Molecular weight markers were used to Saccharomyces cerevisiae strain MC2 was transfacilitate the calculation of the molecular weights for the formed with the p1-gE fragment-expressing plasmids as unknown proteins. previously described (Burns et al., 1991) . Single colonies Proteins separated by SDS-PAGE were transferred were purified by streaking onto fresh plates. The transon to a nitrocellulose membrane (Schleicher and Schuell; formed cells were grown selectively in 50 ml SC-glc 0.45 m; BA85) using a wet Western blotter (Mini-protean medium at 30Њ for 24 hr with agitation. This was used to II, Bio-Rad). A constant current of 100 V for 1 hr was innoculate 500 ml SC-glc medium supplemented with applied to transfer the proteins. The membranes were 10 g/liter galactose until a cell density of 4-6 1 10 7 /ml then thoroughly washed with distilled water and incuwas reached (Ç18 hr). The yeast cells were harvested bated with blocking buffer [PBS containing 5% (w/v) at 4200 rpm (5000 g) for 20 min, washed three times in skimmed milk (Marvel)] for 1 hr at room temperature (RT). TEN buffer [0.1 M NaCl, 10 mM Tris-HCl (pH 8.0) conThe membranes were washed three times (5 min each taining 1 mM EDTA (pH 8.0)] and VLPs were released wash) with PBS/Tween 20 (0.05% v/v) and incubated for by vortexing cells with glass beads (40 mesh; BDH). The 1 hr at RT with test sera or MAb diluted in blocking buffer. clarified homogenate was spun at 9000 rpm (11,000 g) Then, the membranes were washed, as before, and incufor 20 min and particles partially purified by centrifugation bated with peroxidase-labeled anti-human or anti-mouse at 100,000 rpm (541,000 g) for 17 min on to a 60% sucrose IgG conjugate (Sigma) diluted 1/50 in blocking buffer. The cushion with a second centrifugation for 40 min onto a membranes were washed and developed with a solution 35-60% cushion. The VLPs were resuspended in sterile containing nickel chloride (2% w/v, 0.3 ml), 3,3-diamino-PBS. The formation of gE fragment-VLPs was deterbenzidine (1 mg/ml, 1.5 ml), hydrogen peroxide (0.002% mined by SDS-PAGE analysis. This material is referred v/v, 30 ml) in PBS (13.2 ml). The reaction was stopped to as ''spin-prep'' VLPs and the purity is generally bewith distilled water and the membranes were dried in tween 40 and 60%.
the dark. The intensity of the bands was scored from The hybrid gE fragment-VLPs selected for further // to 0 after subtracting any nonspecific reactivity with studies were produced at 12 liter scale fermentation and purified by fractionation on a 35-60% sucrose gradient control nonhybrid VLPs. 2) was prepared and immediately added to the plates. After 15 min, the reaction was RESULTS stopped by addition of sodium fluoride (2.5% w/v). The optical density values were measured spectrophotometFormation of hybrid gE fragment-VLPs rically at 405 nm. The reactivity of the sera and MAbs A series of vectors for the production of gE fragmentwere scored from // to 0 after subtracting any nonspeVLPs in yeast was constructed (Table 1) . gE DNA fragcific reactivity with control nonhybrid VLPs. ments were inserted into the unique BamHI site of pOGS40, the Ty p1 expression vector (Adams et al., Inhibition ELISA 1991) . The resulting plasmids were used to transform Pooled zoster sera, PZ6 at 1/200 dilution was incuyeast and the expression of fusion proteins induced in bated with VZV antigen or gE fragment-VLPs (200 mg/ the presence of galactose. The cells were then homogeml) overnight at 4Њ followed by centrifugation at 3000 rpm nized and the debris was removed by centrifugation. The (1000 g) for 30 min. The supernatants were transferred to supernatant was then centrifuged onto a sucrose cush-ELISA plates previously coated with VZV antigen, control ion and the deposit (VLPs) was resuspended and centriantigen, or gE fragment-VLPs. Direct ELISA was then fuged again onto a second sucrose gradient. During this performed, as described.
procedure VLPs, but not monomeric fusion protein or yeast proteins, pass through and are partially purified.
Pepscan analysis
Samples from this spin-prep procedure were run on SDS-PAGE gels to confirm that fusion proteins of the Twenty-four synthetic peptides were synthesized by correct size were present. The expression of p1-carrying the multiple peptide system (ZENECA Ltd.). The 20-mer fragments 1, 2a, 2b, and 3 produced fusion proteins that peptides covered the 1-135 gE VZV sequence and overassembled into hybrid VLPs, while the expression of p1 lapped by 15 amino acids. The peptides were diluted to carrying the other fragments produced no (fragments 4 30-40 mg/ml in coating buffer (pH 9.6) and ELISA plates were incubated overnight at 4Њ with 50 ml/well. Each peptide was coated in quadruplicate. Direct ELISA was then 
Note. Strong (//), medium (/), weak (//0), and negative (0) antibody responses. Percentage positive sera in parentheses. Average response of 7 chickenpox sera a and 10 zoster sera including a pool of 6 sera. b ND, not determined.
and 5) or low (fragment 6) levels of VLPs. Although VLPs preparations probed with PZ6 zoster serum pool and MAb IF-B9. The bands above the dominant band on were not produced for the last three fragments, sufficient fusion protein was produced to enable antigenic analysis gE(1-134)-VLPs represent multimers of the p1 fusion protein which have resisted the denaturing conditions. by Western blot using crude yeast cell lysates. The plasmids and the fragment of gE carried by each hybrid p1
Furthermore, the observed molecular weight of the monomeric p1-gE(1-134) fusion protein is approximately fusion protein are described in Table 1 . gE(1-134)-VLPs, gE(101-161)-VLPs, gE(161-233)-VLPs, and gE(201-63 kDa, whereas the calculated molecular weight is approximately 57 kDa. These anomalies are characteristic 333)-VLPs were produced at 12-liter scale and purified as previously described (Burns et al., 1991) . of the p1 protein by SDS-PAGE analysis (Burns et al., 1991) .
Antigenicity of gE fragment-VLPs
By ELISA, the highest antibody reactivity for all the zoster and chickenpox sera was again obtained using To identify the regions of the gE protein that are most gE(1-134)-VLPs as the antigen (Table 2 ). All the chickimmunogenic in humans following VZV infection, the antienpox and 80% of the zoster sera also reacted well with genicity of the gE fragment:Ty-VLPs was analyzed by gE(101-161)-VLPs and 3/17 sera reacted weakly with Western blotting and ELISA, using serum samples from gE(201-333)-VLPs. MAbs IF-B9 and SG1A showed very individuals with recent chickenpox (7 sera) and zoster (9 high reactivity with the sequence 1-134 of gE and SG1A sera) infections, a pooled serum from six individuals with also reacted with gE(101-161)-VLPs, as in the Western recent zoster infection, and also two neutralizing MAbs.
blot analysis. Table 3 shows the optical density values Table 2 summarizes the reactivities of these samples on from 17 donor sera tested by ELISA against VLPs carthe various VLP antigens. All the samples reacted with rying the immunodominant fragment gE(1-134), in addithe VZV antigen but not control antigen preparation by tion to the VZV and control antigen preparations. The PZ6 Western blotting.
serum was used as a positive control and pooled sera The most intense serum antibody reactivity by Western from three individuals, who had no history of chickenpox blotting was obtained with gE(1-134)-VLPs for all the or shingles, were used as negative control. The pooled chickenpox and zoster sera tested. All the chickenpox PZ6 serum produced a higher reactivity against the conand the majority of the zoster sera were also reactive trol antigen (OD of 0.357) compared to the negative conagainst gE(101-161)-VLPs but did not react significantly trol serum, but showed a strong reactivity to the VZV with the other two hybrid VLPs covering amino acids antigen and the gE(1-134)-VLPs. All the sera reacted 161-333 (apart from weak reactivity with one chickenpox with the VZV antigen while 7/8 chickenpox and 7/9 zoster serum on gE(201-333)-VLPs) or the cell homogenates sera reacted with the gE(1-134)-VLPs. None of these from yeast transformed with pOGS1211-1213 (expresssera reacted with nonhybrid control VLPs apart from PZ6 ing fragments covering residues 303-623). The producwhich showed some nonspecific reactivity (data not tion of p1 fusion protein in these yeast cell homogenates shown). was confirmed by blotting with a MAb to the Ty p1 protein
In order to confirm that the antibodies binding to the (data not shown). The two gE-specific MAbs reacted gE(1-134)-VLPs also bind to native VZV gE, the human strongly with gE(1-134)-VLPs and SG1A also reacted, PZ6 serum was adsorbed with VZV antigen prior to testto a lesser degree, with gE(101-161)-VLPs. Figure 1 ing in the ELISA assay on VZV antigen, control antigen, shows typical Western blots of hybrid and control VLPs, VZV, and control (noninfected cell lysate extract) antigen and gE(1-134)-VLPs. The unabsorbed and preabsorbed cell epitopes in this region in more detail using pepscan analysis. Ten human sera showing strong reactivity against gE(1-134)-VLPs by ELISA (PZ6 zoster serum pool, 4 zoster sera, and 5 chickenpox sera) and the two MAbs IF-B9 and SG1A were analyzed in the pepscan assay using overlapping peptides representing gE(1-135). All the samples, except SG1A gave identifiable peaks of activity and representative histograms of peptide reactivity are shown in Fig. 2 . For each epitope recognized, in most cases, three or four sequential peptides were positive because B cell epitopes are generally 3-6 amino acids in length. In some cases, however, individual peptides were positive at a weak level and this may represent the peak peptide of a group of 3 or 4. Assuming an epitope size of 6 amino acids, a 10-amino-acid sequence containing the epitope could be defined, consisting of the last 5 amino acids of the peptide immediately prior to a triplet of positive peptides and the first 5 amino acids of the peptide immediately after the triplet. However, where epitope reactivities overlapped, i.e., 4 or more peptides were positive, it was not possible to resolve an epitope to less than 20 amino acids.
The pepscan results are summarized in Table 4 which shows the most immunodominant sequences recognized by the zoster and chickenpox sera and the MAb IF-B9. An epitope in HEHHGVYNQG (residues 96-105 in peptide 18) was detected by all chickenpox and zoster sera. An epitope in LGDDTGIHVI (126-135 in peptide 24) was detected by all chickenpox sera and 4/5 zoster sera and Having identified gE(1-134) as the main immunodomi- an epitope in residues 56-75 (peptide 12) was recogseparate assays. The MAb IF-B9 gave a clear pattern of reactivity with three peptides only (Fig. 2) and recognized nized by 3/5 zoster and 2/5 chickenpox sera. An epitope in SRKAYDHNSP (71-80 in peptide 14) was recognized an epitope in the sequence YIWPRNDYDG (81-90). by all chickenpox sera but was not recognized by any of the zoster sera. Very weak binding of some chickenpox DISCUSSION sera to epitopes in peptides 8 (4/5 sera) and 1 (2/5 sera) and some zoster sera to epitopes in peptides 15 (3/5 In order to identify the immunodominant regions of the VZV gE membrane glycoprotein we have produced virussera), 11 (2/5 sera), 6 (2/5 sera), and 8 (1/5 sera) were detected. One serum (Z4) gave a very high binding to like particles carrying overlapping fragments of the 73-kDa polypeptide. This protein is modified to produce the peptide 15 with no reactivity to flanking peptides in two 
Note. The residues shown in bold represent the shortest definable epitope. NA, not applicable. Serum reactivity, arbitrary scoring of ELISA reactivity of sera on peptide-coated plates. mature glycosylated form of gE of 98 kDa, via intermedimany bands in a cell-extracted VZV antigen preparation by Western blot analysis (Harper et al., 1988) and this ates of 81 and 90 kDa (Grose, 1990) . Six of the seven plasmids expressing p1-gE fragment fusion proteins confirms that gE is not the only major antigen and therefore not the only potential vaccine candidate. All sera produced hybrid VLPs in yeast, as assessed by spinprep analysis (see Materials and Methods). However, tested from individuals with recent chickenpox or zoster infections reacted with the VZV antigen by ELISA and 14/ three produced insufficient levels of VLPs for purification but did generate sufficient p1-gE fusion protein for anti-17 of these sera were also positive on gE(1-134)-VLPs. Of the three that were negative, two also showed relagenic analysis. It is not clear why plasmids expressing p1 fused to sequences from the C-terminal of gE (resitively weak reactivity on the VZV antigen. The sera tested in this study were taken within 4 months of infection. dues 303-623) produce low levels of protein and/or failed to produce particles in yeast. The region The time of sampling the sera following infection will obviously effect the levels of anti-VZV antibody in the contains 6 cysteine residues with two further cysteines at positions 552 and 559. These may interfere with protein sera and it is conceivable, but unlikely, that the specificity of the response to gE and other proteins may change refolding and the subsequent protein-protein interactions required for VLP assembly. Consistent with this with time. This possibility needs to be investigated. To define the immunodominant sequences more idea is the observation that transformation of yeast with the plasmid expressing p1 fused to residues 303-435 closely, we analyzed 10 sera and 2 monoclonal antibodies by pepscan on synthetic peptides covering residues containing 5 cysteine residues resulted in no detectable VLP formation. There are other ill-defined features of the 1-135. Pepscan analysis revealed that the most immunodominant region for human and mouse antibodies was protein sequence which may also affect the expression levels of p1 fusion proteins and particle formation, for between residues 50 and 135. Three epitopes in sequences 56-75, 86-105, and 116-135 were recognized example, the hydrophobicity of the sequence.
The gE protein can be divided into an extracellular by most chickenpox and zoster sera, with the epitope in 86-105 (HEHHGVYNQG) being recognized by all sera domain which spans residues 1-584 including a membrane proximal region between residues 548 and 584, tested. All chickenpox, but no zoster sera reacted strongly with an epitope in sequence 66-85 (SRKAYDthe transmembrane domain of gE between residues 585 and 601, and the cytoplasmic tail comprising residues HNSP), while epitopes in peptides 15, 11, and 6 were recognized weakly by some zoster but not chickenpox 602-623. The sequence of gE displays many features in common with sequences of many cell surface receptors; sera. It is not clear if these epitopes are chickenpox or zoster-specific and more sera will have to be tested to for example, the TNF-like receptors and indeed the gE molecule bind human IgG via its Fc region (Litwin et al., evaluate this. It may also be the case that testing further sera may reveal additional epitopes. A neutralizing 1992). One would expect, therefore, that the extracellular domain would contain the immunodominant region(s) mouse MAb IF-B9 reacted with sequence 71-90 and the epitope is within the sequence YIWPRNDYDG. This since this is the domain of gE on the virus and on VZVinfected cells which would interact with the immune sysepitope appears to be distinct from those recognized by the human sera tested, although smaller peptides will tem. In antigenicity studies, using human sera from individuals who had recent chickenpox or zoster infections, be required to precisely define individual epitopes for both human sera and MAbs. The difference in epitope this supposition proved to be the case and the most antigenic fragments of gE expressed on VLPs were resirecognition between mice and humans may be related to the form of antigen presentation; i.e., live infection in dues 1-134 and 101-161. Two neutralizing MAbs, IF-B9 and SG1A, also reacted with VLPs carrying residues 1-humans versus active immunization with adjuvant in mice. Surprisingly, the MAb SG1A did not bind to any 134 and we have also observed that another gE-specific MAb, 3B3 (Grose et al., 1983 ) also reacts with gE(101-peptide even though it bound strongly to gE(1-134)-VLPs and, to a lesser degree, to gE(101-161)-VLPs. 161)-VLPs (data not shown). Therefore, the region 1-161 is immunodominant and little or no antigenicity was This MAb reacted well with native gE in the VZV antigen preparation and it may recognize a conformational or observed to the remainder of gE (residues 161-623) assessed by Western blot and ELISA of the hybrid VLPs or discontinuous epitope which is present in gE(1-134)-VLPs but not represented by the set of linear 20-mer by Western blot analysis of cell homogenates containing p1-gE fragment fusion protein.
peptides which overlap by 15. The mapping studies have identified sequences in gE The reactivity of serum antibodies against gE(1-134)-VLPs could be absorbed using VZV antigen containing which contain the immunodominant B cell epitopes and these may be useful in a human prophylactic vaccine native gE. However, preincubation of a pool of zoster sera with gE(1-134)-VLPs did not significantly diminish against chickenpox and possibly zoster infections. Studies are currently continuing to define these epitopes preits reactivity with VZV antigen by ELISA. This is not surprising since this serum and most zoster sera react with cisely and to answer the most important question as to B CELL EPITOPES IN VZV gE for Gene Expression'' (M. Collins, Ed.), Vol. 8, whether antibodies recognizing the human epitopes on Press, Clifton, NJ. gE are neutralizing. VLPs carrying the MAb IF-B9-defined Davison, A. J., and Scott, J. E. (1986) . The complete DNA sequence of neutralizing epitope or one or more of the human B cell varicella-zoster virus. J. Gen. Virol. 67, 1759 -1816 epitopes may be potential VZV vaccine candidates. We Dubey, L., Steinberg, S. P., La Russa, P., Oh, P., and Gershon, A. A.
are also assessing the immunogenicity of gE(1-134)- (1988 dues 1-135 it will be possible to detect and map epi- Gershon, A. A. (1975 
